Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00977938 · ClinicalTrials.gov registry record · Phase 4
The Dual Antiplatelet Therapy Study (DAPT Study)
A Phase 4 study, sponsored by Baim Institute for Clinical Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 25,682
- Enrollment target
NCT00977938 is a Phase 4 study that has completed, run by Baim Institute for Clinical Research. The registered enrollment target is 25,682 participants.
The verdict
NCT00977938, a Phase 4 study, has completed, sponsored by Baim Institute for Clinical Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25,682 participants
- Enrollment target
Study Summary
The DAPT Study is a double blind randomized controlled trial intended to determine the appropriate duration for dual antiplatelet therapy (the combination of aspirin and a second anti-clotting medication) as well as the safety and effectiveness of dual antiplatelet therapy to protect patients from stent thrombosis and major adverse cardiovascular and cerebrovascular events (MACCE) following the implantation of drug-eluting coronary stents. Similar analysis will be conducted in a smaller cohort of bare metal coronary stent - treated subjects.
Interventions
- DRUG Placebo & Aspirin
- DRUG Clopidogrel & Aspirin, Prasugrel & Aspirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25,682 participants |
| Start Date | 2009-10 |
| Est. Completion | 2014-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00977938
The ClinicalTrials.gov registry entry for NCT00977938 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 25,682 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baim Institute for Clinical Research, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo & Aspirin is the first listed.
NCT00977938 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00977938 about?
NCT00977938 is a clinical study titled "The Dual Antiplatelet Therapy Study (DAPT Study)". The DAPT Study is a double blind randomized controlled trial intended to determine the appropriate duration for dual antiplatelet therapy (the combination of aspirin and a second anti-clotting medication) as well as the safety and effectiveness of dual antiplatelet therapy to protect patients from s...
What is the current status of trial NCT00977938?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25,682 participants. The study started on 2009-10. Estimated completion is 2014-06.
What interventions are being tested in trial NCT00977938?
The interventions under investigation include: Placebo & Aspirin (DRUG), Clopidogrel & Aspirin, Prasugrel & Aspirin (DRUG).
Who is sponsoring clinical trial NCT00977938?
This trial is sponsored by Baim Institute for Clinical Research, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.